A compound of formula (Ia) or a pharmaceutically acceptable salt thereof, wherein: L 1 is a) C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene, wherein the C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene are each optionally substituted with 1, 2, 3, or 4 fluoro substituents; b) -(CH 2 ) t -G-(CH 2 ) p -; wherein t is 0, 1, or 2, p is 0, 1, 2, or 3, and t+p = 0, 1, 2, 3, or 4; or c) -(CH 2 ) n- G 1 -(CH 2 )p-, -(CH 2 ) n- G 2 -(CH 2 ) p -, -(CH 2 ) n -C≡C-G 2 -, or-(CH 2 ) n -C(R 13 )=C(R 13 )-G 2 -, wherein n is 1, 2, 3, 4, or 5, p is 0, 1, 2, or 3, and n+p = 1, 2, 3, 4, 5, or 6; G is or G 1 is O, C(O), S, S(O), S(O) 2 , or NR 8 ; wherein R 8 is H, C 1 -C 4 alkyl, or C 1 -C 4 alkylcarbonyl; G 2 is or wherein G 2 is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 3 haloalkyl, cyano, halogen, C 1 -C 3 alkoxy, and C 1 -C 3 haloalkoxy; R 1 is COOR 10 , CONR 10 R 11 , CH 2 OR 10 , SO 3 R 10 , SO 2 NR 10 R 11 , PO(OR 10 ) 2 , or tetrazol-5-yl; R 10 is H, C 1 -C 4 alkyl, or aryl; R 11 is H, C 1 -C 4 alkyl, COR 12 , OR 10 , or SO 2 R 12 ; R 12 is C 1 -C 4 alkyl; R 13 , at each occurrence, is independently H or C 1 -C 4 alkyl; L 4 is -C(R 2 ) 2 -C(R 3 ) 2 -, -C(R 2 )=C(R)- , -C≡C-, or wherein R 2 and R 3 are each H, CH 3 , fluoro, or choro; L 2 is a bond; R 4 and R 5 are each independently H, F, CF 3 , or C 1 -C 4 alkyl; or R 4 and R 5 together with the carbon to which they are attached form a C 3 -C 5 cycloalkyl, R 6 is C 3 -C 10 alkyl, C 3 -C 10 alkynyl or L 3 -R 7 , L 3 is C 1 -C 6 alkylene, R 7 is phenyl, r is 0 or 1; and s is 1. L 1 is a) C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene, wherein the C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene are each optionally substituted with 1, 2, 3, or 4 fluoro substituents; b) -(CH 2 ) t -G-(CH 2 ) p -; wherein t is 0, 1, or 2, p is 0, 1, 2, or 3, and t+p = 0, 1, 2, 3, or 4; or c) -(CH 2 ) n- G 1 -(CH 2 )p-, -(CH 2 ) n- G 2 -(CH 2 ) p -, -(CH 2 ) n -C≡C-G 2 -, or-(CH 2 ) n -C(R 13 )=C(R 13 )-G 2 -, wherein n is 1, 2, 3, 4, or 5, p is 0, 1, 2, or 3, and n+p = 1, 2, 3, 4, 5, or 6; a) C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene, wherein the C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene are each optionally substituted with 1, 2, 3, or 4 fluoro substituents; b) -(CH 2 ) t -G-(CH 2 ) p -; wherein t is 0, 1, or 2, p is 0, 1, 2, or 3, and t+p = 0, 1, 2, 3, or 4; or c) -(CH 2 ) n- G 1 -(CH 2 )p-, -(CH 2 ) n- G 2 -(CH 2 ) p -, -(CH 2 ) n -C≡C-G 2 -, or-(CH 2 ) n -C(R 13 )=C(R 13 )-G 2 -, wherein n is 1, 2, 3, 4, or 5, p is 0, 1, 2, or 3, and n+p = 1, 2, 3, 4, 5, or 6; G is or G 1 is O, C(O), S, S(O), S(O) 2 , or NR 8 ; wherein R 8 is H, C 1 -C 4 alkyl, or C 1 -C 4 alkylcarbonyl; G 2 is or wherein G 2 is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 3 haloalkyl, cyano, halogen, C 1 -C 3 alkoxy, and C 1 -C 3 haloalkoxy; R 1 is COOR 10 , CONR 10 R 11 , CH 2 OR 10 , SO 3 R 10 , SO 2 NR 10 R 11 , PO(OR 10 ) 2 , or tetrazol-5-yl; R 10 is H, C 1 -C 4 alkyl, or aryl; R 11 is H, C 1 -C 4 alkyl, COR 12 , OR 10 , or SO 2 R 12 ; R 12 is C 1 -C 4 alkyl; R 13 , at each occurrence, is independently H or C 1 -C 4 alkyl; L 4 is -C(R 2 ) 2 -C(R 3 ) 2 -, -C(R 2 )=C(R)- , -C≡C-, or wherein R 2 and R 3 are each H, CH 3 , fluoro, or choro; L 2 is a bond; R 4 and R 5 are each independently H, F, CF 3 , or C 1 -C 4 alkyl; or R 4 and R 5 together with the carbon to which they are attached form a C 3 -C 5 cycloalkyl, R 6 is C 3 -C 10 alkyl, C 3 -C 10 alkynyl or L 3 -R 7 , L 3 is C 1 -C 6 alkylene, R 7 is phenyl, r is 0 or 1; and s is 1. <EOS>